Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

The Adjuvant! Online software was used to divide the same population into high-risk (n = 152) and low-risk (n = 46) groups on the basis of clinical factors. Among patients classified as low risk ...

Updated results from the KATHERINE trial showed that adjuvant T-DM1 provided a significant improvement in overall survival and no evidence of long-term safety issues.